Hétérocycles azotés (N)

2,6-Dichloropurine is a nitrogenous base that inhibits the activity of certain enzymes in the body. It has been shown to inhibit protease activity and nitro reductases, which are enzymes that metabolize nitrosamines. 2,6-Dichloropurine also inhibits the synthesis of epidermal growth factor (EGF) and adenosine A3 receptors in vivo. This drug has potent antitumor activity against various cancer cells and is used for the treatment of HIV infections. 2,6-Dichloropurine can be synthesized from 6-fluoro-3-indoxyl-beta-D-galactopyranoside with an intramolecular hydrogen atom.

5-Bromo-2-methoxypyridine is a synthetic organic chemical that is used in organic chemistry. It is a precursor to the HIV integrase inhibitor, PSC 833, and has been shown to be effective in treating idiopathic pulmonary fibrosis. 5-Bromo-2-methoxypyridine is synthesized by reacting phosphorus oxychloride with 2-bromomethoxybenzene. This reaction produces a mixture of products that are then separated using column chromatography. The desired product can be purified by recrystallization or distillation. 5-Bromo-2-methoxypyridine has three pairs of asymmetric carbon atoms and four different functional groups: halides, sulfur trifluoride, bromine, and methoxy groups.

5-Bromo-2-chloro-3-methoxypyridine is a kinase inhibitor that belongs to the class of compounds called analogues. This compound has been shown to be an efficient, selective and potent inhibitor of the csf1R protein kinase. 5-Bromo-2-chloro-3-methoxypyridine has also been shown to inhibit the activity of other kinases such as cdc2, cdk4, cdk6 and cdk7. The structure of this compound was used as a starting point in the development of a new class of kinase inhibitors.

2-Amino-3-chloropyrazine is an active analogue of pyrazinamide, which is a potent antimycobacterial drug. It has been shown to have bacteriostatic activity against Mycobacterium tuberculosis in vitro and in vivo. 2-Amino-3-chloropyrazine has been shown to inhibit mitochondrial membrane potential, which may be due to its ability to inhibit hepg2 cell growth by decreasing intracellular ATP levels. It also inhibits the synthesis of bacterial DNA and protein, thereby inhibiting bacterial growth. 2-Amino-3-chloropyrazine has also been shown to have antitumor properties against mouse tumor cells. The pharmacokinetic properties of this drug are not well understood yet, but it has been shown that it can be detected in serum after administration

6-Chloropyridazine-3-thiol is a potent inhibitor of platelet aggregation. This drug binds to the active site of the enzyme ADP-thrombin, thereby blocking the conversion of ADP to thrombin. 6-Chloropyridazine-3-thiol has been shown to have a high affinity for human liver microsomes, and is metabolized by conjugation with glutathione or glucuronide. 6CpT also inhibits the activation of factor V and factor VIII, which are involved in blood clotting. It is hypothesized that this inhibition may be due to its ability to bind to reactive chlorine atoms found on these proteins. 6-Chloropyridazine-3-thiol is a potent inhibitor of platelet aggregation, but it does not show any antiplatelet activity when used at low doses.

4,6-pyrimidinedicarboxylic acid is a synthetic compound that is used as a pharmaceutical preparation. It has been shown to have minimal inhibitory concentrations against many bacterial species, including Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus. 4,6-pyrimidinedicarboxylic acid has shown antibacterial activity in the presence of a halogeno or hydroxyl groups. This compound also has matrix metalloproteinase inhibiting activity and can be used to treat degenerative diseases such as cancer or Alzheimer's disease. 4,6-pyrimidinedicarboxylic acid has been studied for its light emitting properties and protein–protein interactions. The light emission properties are due to the intramolecular hydrogen transfer between two hydroxyl groups on the molecule.

Please enquire for more information about Methyl 3-amino-6-methylthieno[2,3-b]pyridine-2-carboxylate including the price, delivery time and more detailed product information at the technical inquiry form on this page

1-(4,6-dimethylpyrimidin-2-yl)-3-benzoylthiourea is a versatile compound that can be used in various research applications. It is commonly used as a condensation reagent in the synthesis of sulfonamide derivatives. This compound is also utilized in the development of research chemicals and reagents for various purposes.

5-Fluorodihydropyrimidine-2,4-dione is a drug that inhibits the activity of certain enzymes. It has been shown to inhibit the activity of dehydrogenase in human serum and liver cells. This drug has also been shown to be successful in treating autoimmune diseases. 5-Fluorodihydropyrimidine-2,4-dione is an oral prodrug which is converted into its active form by esterases in the gastrointestinal tract. The enzyme inhibitors are used to increase the bioavailability of the drug. This conversion process can be monitored using urine samples or blood sampling.

7-Azaindole is a reactive chemical that has been shown to be effective in the treatment of skin cancer, as well as hepatic steatosis. The compound can promote the transfer of hydrogen atoms and form a dimer with protonated nitrogen. 7-Azaindole reacts rapidly with nucleophiles such as amines, alcohols, and thiols to form covalent bonds. The reaction mechanism is characterized by an initial protonation step followed by nucleophilic attack or hydrogen transfer from the nucleophile to 7-azaindole. Kinetic studies have demonstrated that the rate of this reaction depends on the concentration of both reactants.

Vortioxetine is a serotonin modulator and reuptake inhibitor which appears to be much more potent on serotonin reuptake inhibition and 5-HT3 receptor antagonism than other interactions with the 5-HT receptor family. This drug binds selectively to 5-HT receptors and inhibits the activity of serotonin reuptake transporters on presynaptic neurons, thereby increasing serotonin concentrations in the brain. It is used for the treatment of major depressive disorder (MDD)and has also been shown to be effective against depression-related symptoms such as sleep disturbances, appetite disturbance, and weight change. Vortioxetine has also been demonstrated to suppress glioblastoma in both ex vivo human tissue samples and in mice. This may indicate vortioxetine signalling cascade activation supresses cancer cell division, and could constitute an effective part of a treatment regime for glioblastoma patients.